Short answer
Fortrea Holdings Inc. (FTRE) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $692M (down 1.4% year over year) with net income of $600,000.
Q3 2026 key financials · XBRL
- Revenue
- $692M
- −1.4% YoY · +2.0% QoQ
- Net income
- $600,000
- +103.8% YoY · +104.5% QoQ
- Operating margin
- 2.2%
- EPS (diluted)
- $0.01
- +106.3% YoY · +107.1% QoQ
Source: XBRL data from the Fortrea Holdings Inc. (FTRE) Q3 2026 10-Q on SEC EDGAR. USD.
Fortrea Holdings Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $691.5M, down 1.4% YoY from $701.3M, driven by lower clinical development and FSP demand
- Direct-cost margin 20.2% vs 17.5% YoY, based on direct costs falling to 79.8% of revenue from 82.5%
- Clinical pharmacology strongest line, revenue increased with higher pass-through costs
- Cash $220.6M vs $131.3M YoY, operating cash flow $72.7M vs $(15.6)M
- Backlog $7.3B after $558M scope adjustment, not expected to materially affect near-term revenue expectations
Risk Factors
- No material changes to risk factors described in the February 26, 2026 Form 10-K
- Carried-forward business risks remain detailed in Part I, Item 1A of the Annual Report
- Forward-looking statement risks reiterated in Part I, Item 2 of the Form 10-Q
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Fortrea Holdings Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.